The convertible senior notes, due in 2025, will be senior unsecured obligations of Tandem and are set to accrue interest payable semiannually in arrears, according to a news release.
San Diego-based Tandem also intends to grant the initial purchasers of the notes an option to purchase up to an additional $37.5 million in notes within a 13-day period beginning on the date when they are first issued.
Tandem’s notes will mature on May 1, 2025, unless they are earlier repurchased redeemed or converted in accordance with their terms before the maturity date. The notes will be convertible at the close of business on the business day preceding Nov. 1, 2024. Tandem may not redeem notes before May 6, 2023.
The insulin pump maker intends to use some of the net proceeds to pay the cost of its privately negotiated capped call transactions, with the remainder set for working capital and other general corporate purposes.